Skip to main content

SARS-CoV-2 and monkeypox: what is common and what is not in a present pandemic versus a potential one—a neuropsychiatric narrative review


Pandemic represents challenging medical emergency as it is usually associated with high rates of mortalities and morbidities. Along the last 2 and half years the world has faced the emergence of severe acute respiratory syndrome corona virus 2 pandemic that caught medical agencies and health authorities by surprise and costed more than half billion morbidities and 6 million mortalities. Unfortunately, the way developed countries contained the novel corona virus was unsatisfactory in means of early quarantines as well as obtaining and distributing an effective vaccine. This failure in management might have been responsible for the emergence of a new potential pandemic caused by monkeypox virus. Along the current review article, a detailed comparison is presented between corona virus and monkeypox virus based on virological characteristics, role of corona virus in monkeypox spread, pathogenesis, neuropsychiatric manifestations, and treatment and management. It is obvious that both viruses have a major role in causing various neuropsychiatric manifestations. Neurological manifestations are either bound directly to the virus spread to central and peripheral nervous system or secondary to triggering an immune reaction. Psychiatric ones are mostly related to stigmatization, isolation as well as changes that takes place in neurotransmitters and their metabolites within the nervous system. Dealing properly with monkeypox virus spread through previously learned lessons from corona virus might protect the world from a new pandemic.


Pandemic is an infectious disease that originates in a confined area (single country or region) under the term epidemic state then spreads on a wide scale to involve different countries, regions, and even continents affecting a large proportion of world’s population [1].

Meanwhile an endemic is a prevalent infectious disease within a specific population confined to geographical area [2].

An example of an endemic disease is malaria that is present mainly in sub-Saharan Africa besides broad geographical zones along the equator yet nearly absent in the rest of the world due to absence of its transmitting vector [3].

Unlike malaria, cholera is another infectious disease that is endemic in sub-Saharan Africa with an outbreak epidemic that can turn to become pandemic if not properly managed. Historically cholera had seven pandemic attacks the latest was in 1961 with emergence of a new strain [4].

Epidemics usually occur secondary to different reasons as reduced general hygiene or low immune system in a community. An example of an epidemic is the cholera epidemic outbreak of Yemen that occurred as a result of the Yemeni war [5].

So, it could be concluded that pandemics originate from uncontrolled epidemics. Since the year 2020 the world is facing a pandemic that originated from a central market in Wuhan city in China that sells food besides animals and other products. It is caused by a novel corona virus and was termed after its commonest presentation being severe acute respiratory syndrome of corona virus 2 (SARS-CoV-2) [6].

SARS-CoV-2 belongs to the same corona viruses that emerged in the beginning of the twenty first century which were termed severe acute respiratory syndrome of corona virus (SARS-CoV) and middle east respiratory syndrome of corona virus (MERS-CoV). SARS-CoV-2 is highly infectious if compared to its earlier ancestors since its lipid envelope where the protein spikes are emerging has some changes in its fusion sites that facilitate better attachment to cells and augment entrance [7].

Moreover, it is continuously mutating and this further facilitates its ability to escape acquired immunity from previous attacks within the same individual and being a novel virus to humans there is already no innate immunity against it.

For such reasons, SARS-CoV-2 pandemic is still running for more than 2 years affecting different body systems with a wide range of autoimmune conditions and diverse neuropsychiatric manifestations that are either a result of direct viral effect or secondary to excessive inflammatory response or crossed immunological reaction [8].

Meanwhile the world is facing another unfamiliar outbreak of a previously considered endemic which is monkeypox (MPX) that has crossed borders in a behavior that is uncommon for endemic diseases [9, 10].

According to World Health Organization (WHO), monkeypox is now considered a health emergency of global concern. MPX also can cause some neuropsychiatric manifestations. Although such manifestations are not fully understood. Yet, it shares similar general viremia related symptoms as well as psychiatric stigmatization that is originating out of fear from an unknown pathogen, its effect and to what extent it is contagious [11,12,13].

Along the current review a comparative presentation between SARS-CoV-2 and MPX regarding their cross-relation, features and neuropsychiatric manifestations as well as ways of management and control is presented (Table 1).

Table 1 Similarities and differences between SARS-CoV-2 and MPX

Main text

SARS-CoV-2 and MPX virology

SARS-CoV-2 belongs to the orthocoronavirinae subfamily that is derived from the Coronaviridae family. It is a single stranded RNA virus that is enveloped in a bilayer of lipid structured envelope with spikes on its surface [14].

SARS-CoV-2 is considered one of the largest known RNA viruses reaching 29.9 kb. This makes it difficult to be transmitted through air-borne transmission, yet it could be transmitted through droplet transmission as well as direct contact with infected surfaces or through aerosol transmission [15].

RNA viruses are liable to mutation secondary to errors that develop in their genetic codes while replicating. Such mutation can result in new strains making it difficult to control a pandemic caused by RNA viruses [16]. SARS-CoV-2 has mutated from its original alpha form to beta, gamma, delta, and omicron with its different clades within the last 2 years [17].

Mutations in SARS-CoV-2 are associated with rapid spread and such spread up till now has infected more than half billion mankind with more than 6 million deaths.

The way through which SARS-CoV-2 gain entrance to the human body is through attaching its spikes to the endothelial cells angiotensin converting enzyme 2 receptors (ACE-2) that are abundant along different organs beginning from the nasal cells, respiratory system, renal system, cardiac, vascular system and nervous system [6].

As for MPX, it belongs to the chordopoxvirinae subfamily that is derived from the Poxviridae family. Unlike SARS-CoV-2, monkeypox is a double stranded 197 kb DNA virus with a lipoprotein envelope and it enters cells through macropinocytosis. Being a DNA virus makes it stable when compared to SARS-CoV-2 as DNA viruses have the ability to proof-read their genome while replicating with a less chance to have mutated forms although not fully impossible [18].

Along its original endemic site being west and central Africa, MPX virus has two clades, one in Nigeria with less mortality rates being 1/100 cases and the other in Democratic Republic of Congo with mortality reaching 1/10 cases while Cameron act as a border zone with the two clades endemic in it [18].

Along its current 2022 cross-border outbreak, MPX had a 15 single nucleotide polymorphism mutation which is an uncommon and a relatively rapid mutation for a DNA virus [19].

Monkeypox spread through close long-term contact with an infected animal as well as through body fluids, until the current 2022 global outbreak with a total of more than 60,000 cases worldwide with only few hundred cases in endemic countries there was no direct wide spread human-to-human transmission [20, 21] (Fig. 1, Table 2). Whether such direct spread among humans who have never traveled to the endemic areas along Nigeria where the running clade worldwide is present is related to SARS-CoV-2 is a question of concern.

Fig. 1
figure 1

World map showing countries with monkeypox cases based on numbers that is obtained from centers of disease control and prevention by 28th of September 2022. countries in yellow represent that numbers of cases detected in single digit (units), red represent detected cases in tens, green represent detected cases in hundreds, blue represent detected cases in thousands, and black represent detected cases in tens of thousands

Table 2 Countries with reported cases of spreading monkeypox based on centers for disease control and prevention from 17th of August to 28th of September 2022

Is MPX spread related to SARS-CoV-2?

Infection with SARS-CoV-2 is associated with reduction in total leucocytic count and lymphopenia in many cases. Such low circulatory immune cells count can make infected cases with SARS-CoV-2 more liable for co-infection with MPX and this in turn may be associated with change in form and course of infection in one or both diseases as well as response to vaccination [22].

Another link between SARS-CoV-2 and MPX outbreak is absence of immunity in young generations against smallpox virus since stopping its vaccination campaigns after its eradication in 1980. Smallpox belongs to the same family of monkeypox and stopping the administration of its vaccine aided in relative increase in monkeypox cases in its endemic areas together with reduction in immunity of local residents on top of spreading SARS-CoV-2 that is associated as well in increasing numbers of monkeypox cases [23].

The world failure to equally distribute vaccines against SARS-CoV-2 among developing and developed countries plays a role in increasing the liability for catching SARS-CoV-2 that further reduces the patient’s immunity and increase his liability to have a co-infection with monkeypox. This failure in vaccine distribution is causing backfire on developed world with the cross-border spread of an increasing number of MPX cases [23, 24].

Another possible explanation for the outbreak of endemic Nigerian clade of MPX through many countries worldwide with most of them within the western world is the reduction in restrictions related to travel and lockdown after reaching more than 70% vaccination against SARS-CoV-2 in the developed world and the mass gathering that reached up to 80,000 attendants most of them from the gay and bisexual community along Maspalomas festival in the Canary Island between 5 and 15th May 2022. Such gathering may have played a role in the spread of viruses like MPX in case of the presence of one or more carrier within such gathering [23].

Pathogenesis of SARS-CoV-2 and MPX neuropsychiatric manifestations

SARS-CoV-2 pandemic that is in the form of tides and waves which differs from MPX more linear spread (Fig. 2) have aided different health authorities and organizations to study its pathogenesis along different body systems with nervous system one of them.

Fig. 2
figure 2

Rising cases of monkeypox within 1 month of monitoring

Besides gaining entrance to cells through ACE-2 receptors which causes direct invasion, the commonest pathophysiologic mechanisms responsible for central and to an extent peripheral neurological manifestations of SARS-CoV-2 are attributed to exposure of the immune system to a novel virus with absence of innate immunity previous experience, which is followed by over activity and overexpression of cytokine and chemokine responses that reaches up to triggering autoimmune reactions [25].

Such overexpression of inflammatory and immune markers is reported along different studies that proved the presence of elevated values of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α) besides pleocytosis in examined cerebrospinal fluid (CSF) of SARS-CoV-2 victims [26].

Central nervous system invasion of SARS-CoV-2 is through two routes, first is through hematological spread, where the virus reaches the endothelial cells lining the blood capillaries of the blood brain barrier (BBB) and invades such cells through attaching its spikes to ACE-2 receptors that are abundant within the endothelial cell surfaces and this causes break down in the BBB which in turns causes direct inflammation to the brain and brain edema that could compress vital centers along the brainstem with further affection of respiratory and circulatory systems. Second route is retrospectively either from the endothelial cells lining the olfactory bulb and along the olfactory pathway to the CNS or from chemo and mechanoreceptors of the respiratory system to the brainstem cardiorespiratory system [27,28,29].

Pathogenesis behind peripheral nervous system disorders associated with SARS-CoV-2 is either secondary to direct viral infection and that is why some literature reported cases were having a para-infectious presentation or secondary to triggering the immune system through molecular mimicry to attack the myelin sheath with post-infectious presentation [30,31,32].

Psychiatric manifestations presenting with SARS-CoV-2 is attributed to the lockdown and curfew that was declared along the initial waves of the pandemic which deprived medically chronic patients of their usual checkups with their treating physicians besides the media effect of presenting mortalities with daily counts that had direct mental traumatizing effect. Social distancing is also a main trigger to frustration, aggression, mood disorders, insomnia and psychosis [33, 34].

Stigma from being infected with fear of transmitting infection also played a role in overexpression of psychiatric manifestations besides the changes that develop along neurotransmission pathway and its metabolites triggered indirectly by stress and directly by the immune response effect to the virus on such neurotransmitters [35].

Kucukkarapinar and colleagues succeeded in linking psychiatric manifestations that takes place post SARS-CoV-2 exposure to the kynurenine pathway and tryptophan metabolism. Infection with SARS-CoV-2 alter the tryptophan pathway with increase in kynurenic acid, kynurenine, and quinolinic acid and decrease in tryptophan which in turn increases oxidative stress, and impairs glutamate action with a net affection on cognitive functions. Meanwhile increase in conversion of tryptophan to kynurenine is associated with reduction in serotonin that can explains psychiatric manifestations accompanying infection with SARS-CoV-2 as depression and anxiety [35].

As for neurological manifestations pathogeneses of MPX up till now are mainly attributed to inflammatory viremia effects of the virus causing fever that in turns affect muscles leading to myalgia. Raised body temperature is associated with tachycardia, tachypnea, hypercapnia up to hypoxia which affects all body systems and can cause headache, encephalopathy up to seizures in vulnerable cases [36].

Psychiatric pathogeneses of MPX are to a great extent stigma related especially that most available data are speaking on homosexuality role in transmission of MPX. And since it is a relatively recently human-to-human transmitted disease, its stigma originates from lacking full medical knowledge about it that resembles what epilepsy had in the ancient civilization thoughts [37].

Neuropsychiatric aspects of SARS-CoV-2 and MPX

Unlike its name, SARS-CoV-2 does not just cause influenza like manifestations. Along the last 2 and half years since its declaration as a pandemic by WHO in March 2020, SARS-CoV-2 affected the nervous system in a plenty of ways.

Such affection is either central or peripheral, sometimes preceded the respiratory manifestations, and in other occasions is either conjoint with it or appears few weeks following diagnosis [8].

These different phases of neurological affection spotlight on the diverse pathophysiology of neurological complications of SARS-CoV-2 [8, 38].

Neurovascular complications of SARS-CoV-2 whether in the form of ischemic strokes or hemorrhagic ones and whether arterial or venous are very common and are reported with mild, moderate, or severe forms of SARS-CoV-2 [39, 40].

Stroke in some cases is the only manifestation of SARS-CoV-2. Its pathophysiology was described by Roushdy and Hamid which is related to uncontrolled rise in blood pressure secondary to down regulation in ACE-2 receptors that are used by SARS-CoV-2 spikes to gain entrance to endothelial cells, reduction in platelet count, disturbance in coagulation parameters whether procoagulants or anticoagulants as well as cytokine storm and elevated inflammatory biomarkers that can affect vessel wall integrity and induce vasculitis [6].

Besides the usual symptoms accompanying any viremia being myalgia, bony aches, fatigue, anorexia and fever, it is noticed that SARS-CoV-2 is associated with anosmia in many cases. Anosmia is believed to be secondary to viral invasion of olfactory nerve endings within the cribriform plate that is lined by endothelium cells abundant with ACE-2 [41].

Besides dysfunction of the olfactory nerve, other cranial nerves are occasionally affected following SARS-CoV-2 infection and secondary to long-term treatment with steroids in patients who are usually immunocompromised. Such patients might catch rhino-orbito-cerebral mucormycosis with infiltration of the orbital cavity, or nasal sinuses with affection of oculomotor, abducent, trochlear and optic nerves with or without cavernous sinus thrombosis [42, 43].

Encephalitis is also reported with SARS-CoV-2 that is explained as direct invasion of the virus through the nasal cavity and backflow through the olfactory nerve to the brain. Yet evidence supporting this explanation is weak as analysis of cerebrospinal fluid of patients along plenty of cases failed to detect the viral RNA through reverse transcription polymerase chain reaction (PCR). Yet encephalitis with SARS-CoV-2 is suggested to be a result of direct immune reaction releasing cytokines, chemokines and inflammatory biomarkers within the central nervous system [8, 38].

Peripheral nervous system is also involved in acute cases. Many reports spoke about peripheral neuropathy and autoimmune reactions with autoantibodies against the peripheral nervous system causing Guillain–Barre spectrum syndromes few weeks after a negative PCR [44].

Many of the cases that recovered the acute phase of illness suffer a diverse natured symptom; such cases are termed long Covid. Neurological and psychiatric symptoms are the commonest in long Covid. Such symptoms range between fatigue, lack of concentration, inattention, memory lapses, generalized weakness, sleep disturbance, depressive or anxiety symptoms, post-traumatic stress, chronic headaches, autonomic dysfunctions. Psychiatric manifestations may reach up to delusions [45, 46].

Long Covid symptoms are much like the myalgic encephalomyelitis/chronic fatigue syndrome symptoms [47].

Autopsy of the brain of SARS-CoV-2 victims showed widespread of macrophages and inflammatory infiltrates as well as microglia within the brain and disruption of the blood brain barrier; such findings highlight the possibility of developing neurodegenerative conditions in the future as Parkinson’s and Alzheimer’s diseases [8, 48]

As for young children who catch SARS-CoV-2, the usual symptoms are mild and do not extend beyond the general viremia signs. Yet, few develop the rare multisystem-inflammatory syndrome in children (MIS-C) which is associated with excessive endothelial activation and this might be accompanied by neurological manifestations that range between mild symptoms as headache and anosmia, and can extend up to meningitis, seizures, encephalopathy, cerebellar ataxia, proximal myopathy and bulbar palsy. Such neurological manifestations are secondary to immune system overactivation with autoimmune reactions [49].

Unlike SARS-CoV-2, MPX virus has few reported neuropsychiatric manifestations, yet such statement might be misleading in the context that MPX cases are still in the range of thousands if compared to millions studied cases in SARS-CoV-2.

Reported neuropsychiatric manifestations of the endemic MPX are headache, myalgia, photophobia, pain and fatigue, seizures, encephalitis, anxiety, and depression that can mount up to suicide [50,51,52].

Fatigue, myalgia, and headache can be attributed to the viremia that is common with any viral infection [53]. As for psychiatric manifestations that ranges from anxiety up to major depression with suicidality it could be explained on basis of fear of stigma as most historical patients were hospitalized in quarantine hospitals [54].

Encephalitis was reported in cases along endemic regions of west and central Africa and also was previously reported in 2 pediatric cases both were diagnosed by MPX, and only one of them was subjected to cerebrospinal fluid analysis that showed antibodies (IgM) against the virus yet no evidence of the virus itself which could be explained on immunological basis rather than direct invasion of the brain by the virus [55, 56].

Along the current cross-border outbreak besides three deaths in Nigeria, two in Central African Republic, and one in Ghana, there are 2 reported deaths in Spain, one in Brazil and one in India. The two deaths in Spain are secondary to encephalitis and meningoencephalitis.

Despite SARS-CoV-2 manifestations in children are mild yet manifestations of MPX in children may be severe [56].

Preventive measures and management

Being viruses, the general recommendation by different health authorities is just symptomatic treatment for symptoms as the use of analgesics and antipyretics to guard against constitutional symptoms as fever, headache and body aches is applied.

As for current National Institutes of Health (NIH) guidelines for SARS-CoV-2 it is divided into two phases. The first one is targeting the virus itself while in the phase of early infection and replication and the second one is targeting the dysregulated immune system [57].

Aggressiveness of treatment is also based on the illness status whether mild, moderate or severe as well as critically ill. For those who are not hospitalized, dexamethasone or any kind of systemic corticosteroids is not recommended.

As for those patients who are not hospitalized but are at risk of passing into severe form of SARS-CoV-2 infection as those who are immunocompromised or diabetics with uncontrolled diabetes, antiviral medications are to be administered as ritonavir-boosted nirmatrelvir or remdesivir and in case of unavailability then bebtelovimab or molnupiravir could be administered [57].

Hospitalized patients who do not require oxygen supplementation are managed as non-hospitalized but with a prophylactic dose of heparin. Meanwhile, hospitalized patients who are on oxygen support are supplied with dexamethasone besides remdesivir and full-dose heparin in case of elevated d-dimer and not pregnant. As for pregnant patients, prophylactic dose of heparin is recommended.

Intravenous tocilizumab is kept for hospitalized patients with rapid oxygen demands or systemic inflammation. Dexamethasone, remdesivir and intravenous tocilizumab are administered to critically ill patients on high-flow oxygen, non-invasive oxygen, or mechanical ventilation.

As for preventive measures directed against SARS-CoV-2, it is recommended to keep a distance not less than 2 m on dealing with a patient, and an infected patient should wear a face covering, with frequent hand washing of caregiver as well as the patient.

Vaccines are the most reliable preventive ways against SARS-CoV-2 infection. There are four main types of vaccines: whole virus vaccine, RNA or mRNA vaccine, non-replicating virus vector vaccine, and protein subunit vaccine [58].

MPX does not have a definite treatment yet. Brincidofovir and tecovirimat are under investigation for possibility of being effective based on previous partial success on sporadic cases in the United Kingdom. Such medications are still not recommended as a general treatment for all cases, but are left for those immunocompromised, or severely ill [59, 60].

Again, vaccines are the only way to guard against wide spread of MPX. Historically smallpox vaccine used to cause cross-immune protection against other viruses belonging to poxviridae family including MPX. The WHO is recommending to administer new forms of smallpox vaccine for those in medical field who deal with cases of MPX or as a prophylactic treatment within 4 days of contact with a case [61].


Novel SARS-CoV-2 took the world by surprise when it emerged as an epidemic and within few months became a pandemic. SARS-CoV-2 has plenty of neuropsychiatric manifestations that play a great deal in its morbidities. As for MPX, it is an already known virus yet still surprising the unknown mode through which it crossed borders from its endemic areas in west and central Africa to other continents.

Mutations that have been already detected in MPX may have played a role in escaping its endemic region to other regions as well as suspicion of SARS-CoV-2 role in causing mass immunity reduction facilitating the spread of MPX as an opportunistic virus.

As SARS-CoV-2, monkeypox has neuropsychiatric challenges. The world health authorities still have a chance to control and manage MPX and prevent a potential pandemic through lessons learned from SARS-CoV-2.

Limitations and future directions

The current review has some limitations. First, it is an initial narrative review as data regarding monkeypox manifestations are still minimal. Future in-depth reviews including systematic ones will for sure add to the current review.

Second, although presenting a link between two viruses one of them was never faced by the world and another that did not spread to such extent worldwide before although known since the middle of the twentieth century yet such presentation ought to be laboratory checked to confirm the role of lowered immunity caused by one virus in facilitating the spread of another.

Third, indirect role of improper distribution of corona virus vaccine along developing countries in monkeypox spread needs in-depth research and accordingly proper future guidelines on medical services and preventive medicine distribution ought to be implemented by the world health authorities.

Availability of data and materials

The corresponding author takes full responsibility for the data, has full access to all of the data, and has the right to publish any and all data separate and apart from any sponsor.



Severe acute respiratory syndrome corona virus 2


Severe acute respiratory syndrome corona virus


Middle east respiratory syndrome corona virus


Monkeypox virus


World Health Organization


Angiotensin converting enzyme 2


Polymerase chain reaction




Tumor necrosis factor-alpha


Multisystem inflammatory syndrome in children


National Institutes of Health


  1. Rogers K. “pandemic”. Encyclopedia Britannica, 31 May. 2022. Accessed 11 Aug 2022.

  2. “Principles of Epidemiology in Public Health Practice, Third Edition an Introduction to Applied Epidemiology and Biostatistics”. Centers of Disease Control and Prevention. Retrieved 11 Aug 2022.

  3. World Health Organization. Malaria factsheet.

  4. Huber V. Pandemics and the politics of difference: rewriting the history of internationalism through nineteenth-century cholera. J Glob Hist. 2020;15(3):394–407.

    Article  Google Scholar 

  5. International Coordinating Group (ICG) on Vaccine provision for cholera, meningitis, and yellow fever. World Health Organization. 2020. ISBN 978-92-4-002916-3.

  6. Roushdy T, Hamid E. A review on SARS-CoV-2 and stroke pathogenesis and outcome. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):63.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28(2):174–84.

    CAS  PubMed  Google Scholar 

  8. Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267–9.

    Article  CAS  PubMed  Google Scholar 

  9. El Eid R, Allaw F, Haddad SF, Kanj SS. Human monkeypox: a review of the literature. PLoS Pathog. 2022;18(9):e1010768.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.

    Article  PubMed  PubMed Central  Google Scholar 

  11. World Health Organization. Monkeypox factsheets.

  12. McEntire CRS, Song KW, McInnis RP, Rhee JY, Young M, Williams E, et al. Neurologic manifestations of the World Health Organization’s list of pandemic and epidemic diseases. Front Neurol. 2021;22(12):634827.

    Article  Google Scholar 

  13. Deshmukh P, Vora A, Tiwaskar M, Joshi S. Monkeypox: what do we know so far? A short narrative review of literature. J Assoc Physicians India. 2022;70(7):11–2.

    Article  PubMed  Google Scholar 

  14. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44.

    Article  CAS  Google Scholar 

  15. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Novella IS, Presloid JB, Taylor RT. RNA replication errors and the evolution of virus pathogenicity and virulence. Curr Opin Virol. 2014;9:143–7.

    Article  CAS  PubMed  Google Scholar 

  17. Ding K, Jiang W, Xiong C, Lei M. Turning point: a new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Immun Inflamm Dis. 2022;10(4):606.

    Article  CAS  Google Scholar 

  18. Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Sklenovská N, Van Ranst M. Emergence of monkeypox as the most important orthopoxvirus infection in humans. Front Public Health. 2018;6:241.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Harris E. What to know about monkeypox. JAMA. 2022;327(23):2278–9.

    Article  PubMed  Google Scholar 

  22. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Haider N, Guitian J, Simons D, Asogun D, Ansumana R, Honeyborne I, et al. Increased outbreaks of monkeypox highlight gaps in actual disease burden in Sub-Saharan Africa and in animal reservoirs. Int J Infect Dis. 2022;122:107–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ahmed F, Ahmed N, Pissarides C, Stiglitz J. Why inequality could spread COVID-19. Lancet Public Health. 2020;5(5):240.

    Article  Google Scholar 

  25. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, Nocivelli S, et al. Steroid-responsive encephalitis in Coronavirus Disease 2019. Ann Neurol. 2020;88(2):423–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. 2004;251(10):1227–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–8.

    Article  CAS  PubMed  Google Scholar 

  29. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol. 2005;15(1):17–27.

    Article  CAS  PubMed  Google Scholar 

  31. Hosking MP, Lane TE. The role of chemokines during viral infection of the CNS. PLoS Pathog. 2010;6(7):e1000937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shalash A, Roushdy T, Essam M, Fathy M, Dawood NL, Abushady EM, et al. Mental health, physical activity, and quality of life in Parkinson’s disease during COVID-19 pandemic. Mov Disord. 2020;35(7):1097–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Xiang YT, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. Timely mental health care for the 2019 novel corona virus outbreak is urgently needed. Lancet. 2020;7:228–9.

    Google Scholar 

  35. Kucukkarapinar M, Yay-Pence A, Yildiz Y, Buyukkoruk M, Yaz-Aydin G, Deveci-Bulut TS, et al. Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress. J Neural Transm (Vienna). 2022;129(8):1077–89.

    Article  CAS  Google Scholar 

  36. Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza A infection: a case report and review of the literature. N Am J Med Sci. 2015;7:122–4.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Roushdy T, Wahid El Din M, Abdel Monem Mohamed A, Ibrahem HK, Bedros RY, Hamid E. Concepts behind epilepsy among Egyptian patients. Is it a disease or a possession?! Epilepsy Res. 2021;177:106760.

    Article  PubMed  Google Scholar 

  38. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris). 2021;177(1–2):51–64.

    Article  CAS  Google Scholar 

  39. El Nahas N, Roushdy T, Hamid E, Farag S, Shokri H, Fathy M, et al. A case series of ischemic stroke with coronavirus disease 2019 in two Egyptian centers. Egypt J Neurol Psychiatr Neurosurg. 2020;56(1):120.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Roushdy T, Sharaf NK. Venous and arterial cerebral thrombosis: a COVID-19 dual pathology and single possible etiology-a case report. Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Meng X, Pan Y. COVID-19 and anosmia: the story so far. Ear Nose Throat J. 2021.

    Article  PubMed  Google Scholar 

  42. Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H, Inokuchi R, et al. Clinical features and mortality of COVID-19-associated mucormycosis: a systematic review and meta-analysis. Mycopathologia. 2022;187(2–3):271–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Roushdy T, Hamid E. A case series of post COVID-19 mucormycosis-a neurological prospective. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):100.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve. 2020;62(4):485–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Efstathiou V, Stefanou MI, Demetriou M, Siafakas N, Makris M, Tsivgoulis G, et al. Long COVID and neuropsychiatric manifestations (Review). Exp Ther Med. 2022;23(5):363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tefanou MI, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, et al. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis. 2022;13:20406223221076890.

    Article  Google Scholar 

  47. Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis. 2021;8:20499361211009384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G, et al. COVID-19 and Alzheimer’s disease. Brain Sci. 2021;11(3):305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nepal G, Shrestha GS, Rehrig JH, Gajurel BP, Ojha R, Agrawal A, et al. Neurological manifestations of COVID-19 associated multi-system inflammatory syndrome in children: a systematic review and meta-analysis. J Nepal Health Res Counc. 2021;19(1):10–8.

    Article  PubMed  Google Scholar 

  50. Ogoina D, Iroezindu M, Izibewule JH, Oladokun R, Yinka-Ogunleye A, Wakama P, et al. Clinical course and outcomes of human monkeypox in Nigeria. Clin Infect Dis. 2020;71(8):210–4.

    Article  Google Scholar 

  51. Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, Anebonam U, Neni A, et al. The 2017 human monkeypox outbreak in Nigeria—Report of outbreak experience and response in the Niger Delta University Teaching Hospital, Bayelsa State, Nigeria. PLoS ONE. 2019;14(4):e0214229.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis. 2019;19(8):872–9.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci. 2018;12:386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987;156:293–8.

    Article  CAS  PubMed  Google Scholar 

  56. Sejvar JJ, Chowdary Y, Schomogyi M, Stevens J, Patel J, Karem K, et al. Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis. 2004;190:1833–40.

    Article  PubMed  Google Scholar 

  57. National Institutes of Health (NIH). Covid-19 treatment guidelines. 30 September 2022

  58. Mahroum N, Lavine N, Ohayon A, Seida R, Alwani A, Alrais M, et al. COVID-19 vaccination and the rate of immune and autoimmune adverse events following immunization: insights from a narrative literature review. Front Immunol. 2022;13:872683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998;54(3):693–702.

    Article  CAS  PubMed  Google Scholar 

  60. Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. WHO. Vaccines and immunization for monkeypox: interim guidance, 14 June 2022. 2022.

Download references


Not applicable.


No funds were received to fulfill this work.

Author information

Authors and Affiliations



TR: conceptualization, collection of the scientific data, writing—original draft preparation, writing and editing, figure preparation. The author read and approved the manuscript.

Corresponding author

Correspondence to Tamer Roushdy.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roushdy, T. SARS-CoV-2 and monkeypox: what is common and what is not in a present pandemic versus a potential one—a neuropsychiatric narrative review. Egypt J Neurol Psychiatry Neurosurg 58, 127 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • SARS-CoV-2 virus
  • Coronavirus
  • Pandemic
  • Monkeypox virus
  • Neuropsychiatric manifestations
  • Virology
  • Mortality and morbidity
  • Quarantine
  • Stigma